article Open AccessTop 1% cited
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Oncogene · 2008 · Vol. 27(34) · pp. 4702–4711
D Li✉(Dana-Farber Cancer Institute)Lauren Ambrogio(Dana-Farber Cancer Institute)Takeshi Shimamura(Harvard University)Shigeto Kubo(Beth Israel Deaconess Medical Center)Masaya Takahashi(Beth Israel Deaconess Medical Center)Lucian R. Chirieac(Brigham and Women's Hospital)Robert F. Padera(Brigham and Women's Hospital)Geoffrey I. Shapiro(Brigham and Women's Hospital)Anke Baum(Boehringer Ingelheim (Austria))Frank Himmelsbach(Boehringer Ingelheim (Germany))Wolfgang J. Rettig(Boehringer Ingelheim (Austria))Matthew Meyerson(Brigham and Women's Hospital)Flavio Solca(Boehringer Ingelheim (Austria))Heidi Greulich(Harvard University)Kah Keng Wong(Harvard University)
Lung Cancer Treatments and MutationsQuinazolinone synthesis and applicationsCancer therapeutics and mechanismsErlotinibCancer researchBiologyLung cancerT790MEpidermal growth factor receptorEGFR inhibitorsTyrosine kinaseCancerCyclin-dependent kinase 8
MeSH terms
AfatinibAnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell SurvivalDisease Models, AnimalFemaleHumansLung NeoplasmsMice, NudeMice, TransgenicPhosphorylationQuinazolinesTumor Cells, CulturedTreatment Outcome
Funding
- National Institutes of Health
- National Cancer Institute
Citations
1,434
FWCI
32.10
field-weighted impact
References
38
Percentile
100%
vs. same field & year
Citations per year
Cited by
Targeting RTK Signaling Pathways in Cancer
Cancers · 2015 · 375 citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology · 2013 · 3,181 citations
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
Oncogene · 2009 · 979 citations
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
The Lancet Oncology · 2014 · 1,963 citations
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Journal of Pharmacology and Experimental Therapeutics · 2012 · 858 citations
References
Cancer Statistics, 2006
CA A Cancer Journal for Clinicians · 2006 · 5,336 citations
ERBB receptors and cancer: the complexity of targeted inhibitors
Nature reviews. Cancer · 2005 · 3,292 citations
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
PLoS Medicine · 2005 · 3,519 citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
PLoS Medicine · 2005 · 1,521 citations
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Proceedings of the National Academy of Sciences · 2004 · 4,332 citations
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science · 2004 · 9,380 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.